Amgen remains bound by FTC bundling ban from Horizon Therapeutics acquisition

By ··2 min read

The FTC finalised a consent order resolving its challenge, joined by six states, to Amgen's $27.8 billion acquisition of Horizon Therapeutics. The order bars Amgen from bundling its products with Horizon's Tepezza and Krystexxa, requires prior approval for related acquisitions and imposes 15-year compliance obligations under a monitor.

The Federal Trade Commission finalised a consent order dated December 13, 2023 resolving its challenge to Amgen Inc.'s $27.8 billion acquisition of Horizon Therapeutics plc. The order, which remains in force, bars Amgen from bundling its own products with Horizon's Tepezza and Krystexxa and requires it to obtain prior FTC approval before acquiring competing treatments. Most of its other requirements, including annual compliance reporting, run for 15 years.

The FTC sued to block the deal in May 2023 in the US District Court for the Northern District of Illinois, joined by the attorneys general of California, Illinois, Minnesota, New York, Washington and Wisconsin. The agency alleged that Amgen could use its portfolio of blockbuster drugs to pressure insurers and pharmacy benefit managers into favouring Tepezza, used to treat thyroid eye disease, and Krystexxa, used for chronic refractory gout, or into disadvantaging their rivals. It was the FTC's first litigated challenge to a pharmaceutical merger in more than a decade. Under the final order, Amgen may not condition rebates or contract terms on any of its products on the sale or positioning of Tepezza or Krystexxa, and may not use rebates or contract terms to exclude or disadvantage competing products.

Amgen said it had consistently told the FTC, the courts and the public that it had no reason, ability or intention to bundle Horizon's drugs with its own medicines, and described the commitment as a narrow assurance that would have no impact on its business. The FTC appointed Jeryl L. Hilleman as monitor to oversee compliance, and Amgen publishes the order on its website as required.

The resolution was notable for relying on conduct restrictions rather than the product divestitures that have traditionally settled pharmaceutical merger cases. The case also foreshadowed the FTC's wider focus on how rebate arrangements with PBMs shape formulary decisions, a theme that ran through the agency's September 2024 insulin case against the three largest PBMs.

The order remains active, with monitor oversight and prior-approval obligations in effect. Amgen's earlier federal enforcement history includes a 2019 settlement in which it paid $24.75 million to resolve DOJ allegations that it used independent copay charities to cover Medicare patients' copays for its own drugs.

Cite this report

The Precedent. "Amgen remains bound by FTC bundling ban from Horizon Therapeutics acquisition." August 24, 2026. https://theprecedent.org/article/amgen-remains-bound-by-ftc-bundling-ban-from-horizon-therapeutics-acquisition

Companies in this report